参考文献/References:
[1]潘晶莹.我国川崎病的流行病学特征[J]. 国际儿科学杂志,2013,40(5):66-69.[2]闫小红,刘淑霞,刘云,等.川崎病流行病学特征及冠状动脉损害的相关因素分析[J].临床儿科杂志,2010,28(7):636-639.[3]Tamehiro N,Nishida K,Sugita Y,et al.Ras homolog gene family H (RhoH) deficiency induces psoriasis-like chronic dermatitis by promoting TH17 cell polarization[J].J Allergy Clin Immunol,2019,143(5):1878-1891.[4]Koizumi K,Hoshiai M,Moriguchi T,et al.Plasma Exchange Downregulates Activated Monocytes and Restores Regulatory T Cells in Kawasaki Disease[J].Ther Apher Dial,2019,23(1):92-98. [5]Furue M,Kadono T.The contribution of IL-17 to the development of autoimmunity in psoriasis[J].Innate Immun,2019,25(6):337-343. [6]饶晓红,童文娟,陈丁丁.川崎病并发感染患儿Treg/Th17细胞,免疫功能的变化及临床意义[J].中国医药导报,2020,17(5):91-94.[7]杜忠东.川崎病(精)[M].北京:科技文献出版社,2009:177-182.[8]陈树宝,孙锟.小儿心脏病学前沿:新理论与新技术[M].北京:科学出版社,2015:144-158.[9]胡亚美,江载芳.诸福棠实用儿科学(第7版)(上下)(精)[M].北京:人民卫生出版社,2012:173-181.[10] Fuller MG.Kawasaki Disease in Infancy[J].Adv EmergNurs J,2019,41(3):222-228. [11]Sakurai Y.Autoimmune Aspects of Kawasaki Disease[J].J InvestigAllergol Clin Immunol,2019,29(4):251-261.[12]Kobayashi J.Multiple Coronary Artery Bypass Grafting for Kawasaki Disease-Associated Coronary Artery Disease[J].Ann Thorac Surg,2019,108(3):799-805. [13]张颖,犹登霞,周杰林.典型川崎病与不完全川崎病的临床特征分析[J].中国妇幼健康研究,2018,29(11):124-128.[14]Kong WX,Ma FY,Fu SL,et al.Biomarkers of intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease[J].World J Pediatr,2019,15(2):168-175. [15]Ito R,Katano I,Otsuka I,et al.Exacerbation of pathogenic Th17-cell-mediated cutaneous graft-versus-host-disease in human IL-1β and IL-23 transgenic humanized mice[J].Biochem Biophys Res Commun,2019,516(2):480-485.[16]吴克义,张春丽,陈妙月,等.川崎病合并感染患儿血清T细胞亚群,免疫功能的变化[J].中国卫生检验杂志,2019,29(12):101-103.[17]Xu M,Jiang Y,Wang J,et al.Distribution of distinct subsets of circulating T follicular helper cells in Kawasaki disease[J].BMC Pediatr,2019,19(1):43.[18]Furue K,Ito T,Tsuji G,et al.Psoriasis and the TNF/IL23/IL17 axis[J].G Ital Dermatol Venereol,2019,154(4):418-424. [19]行海舰,李健,肖红玉,等.150例川崎病患儿的冠脉受损的高危因素分析[J].现代生物医学进展,2020,20(21):78-81.[20]Hamada H,Suzuki H,Onouchi Y,et al.Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial[J].Lancet,2019,393(10176):1128-1137.[21]van Stijn-Bringas Dimitriades D,Planken RN,Groenink M,et al.Coronary artery assessment in Kawasaki disease with dual-source CT angiography to uncover vascular pathology[J].EurRadiol,2020,30(1):432-441.